Detalhe da pesquisa
1.
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study.
Cancer Immunol Immunother
; 72(6): 1381-1394, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36695827
2.
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.
Cancer Immunol Immunother
; 72(6): 1365-1379, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36633661
3.
From Monoamine Oxidase Inhibition to Antiproliferative Activity: New Biological Perspectives for Polyamine Analogs.
Molecules
; 28(17)2023 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37687158
4.
Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study.
Anticancer Drugs
; 32(1): 74-81, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33290315
5.
The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?
Int J Mol Sci
; 22(12)2021 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34207825
6.
Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report.
Case Rep Oncol
; 17(1): 264-270, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38362443
7.
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
Mol Diagn Ther
; 28(1): 37-51, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37874465
8.
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
Pathol Res Pract
; 254: 155142, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38277752
9.
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
Pathol Res Pract
; 253: 155008, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38103361
10.
First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3ß/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer's Disease.
ACS Chem Neurosci
; 15(11): 2099-2111, 2024 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38747979
11.
Prostate cancer and novel pharmacological treatment options-what's new for 2022?
Expert Rev Clin Pharmacol
; 16(3): 231-244, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36794353
12.
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma.
Expert Opin Drug Saf
; 22(4): 279-291, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37055875
13.
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study.
Clin Exp Med
; 23(8): 5039-5049, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37535194
14.
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis.
Immunotherapy
; 15(2): 117-126, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36695110
15.
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report.
Front Oncol
; 13: 1310452, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38188286
16.
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.
Cancer Manag Res
; 14: 1945-1960, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35720644
17.
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw.
Curr Oncol
; 29(3): 1709-1722, 2022 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35323342
18.
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy.
Cancers (Basel)
; 14(23)2022 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36497326
19.
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis.
Curr Oncol
; 29(8): 5846-5854, 2022 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36005199
20.
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.
Expert Rev Mol Diagn
; 22(11): 997-1008, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36503370